AUP-55
Solid Tumors (Ovarian, Peritoneal, Bladder, Recurrent Melanoma)
Pre-clinical/Phase 1Active
Key Facts
Indication
Solid Tumors (Ovarian, Peritoneal, Bladder, Recurrent Melanoma)
Phase
Pre-clinical/Phase 1
Status
Active
Company
About Aurealis Therapeutics
Aurealis Therapeutics is a private, clinical-stage biotech leveraging a proprietary 4-in-1 multi-target cell and gene therapy platform. Its lead program, AUP-16, has shown promising Phase 2 results in diabetic foot ulcers, tripling complete wound closure rates. The company is advancing this program while also developing an oncology candidate, AUP-55, and has recently secured CHF 8 million in funding to support its clinical pipeline.
View full company profile